Neurolief to Showcase At-Home Brain Stimulation Therapy for Major Depressive Disorder at APA 2026

13th May, 2026

The company will present Proliv Rx, its FDA-approved physician-directed neuromodulation therapy for adults with major depressive disorder who have not responded adequately to antidepressant medication.

Neurolief will showcase Proliv Rx, its FDA-approved prescription brain stimulation therapy for adults with major depressive disorder, at the American Psychiatric Association Annual Meeting 2026 in San Francisco.

The therapy is intended as an adjunctive treatment for adults with major depressive disorder who have not achieved satisfactory improvement from at least one antidepressant medication. It can be delivered at home or in a clinic through a structured, physician-supervised programme.

The announcement highlights a growing shift in mental health technology toward decentralised care models. Many patients requiring next-step depression treatment face barriers linked to clinic capacity, geography, referral pathways and the need for repeated in-person sessions.

Proliv Rx uses Neurolief’s External Combined Occipital and Trigeminal Afferent Stimulation technology, delivering non-invasive multi-channel stimulation through trigeminal pathways in the forehead and occipital pathways at the back of the head.

The therapy is supported by the MOOD pivotal study, a randomised, double-blind, sham-controlled, multicentre trial in adults with major depressive disorder who had not responded adequately to antidepressant medication. Active treatment showed significantly greater improvement in depressive symptoms than sham at eight weeks.

With continued treatment through 16 weeks, 31.7 per cent of patients achieved remission and 70.7 per cent achieved clinically substantial improvement. Treatment was generally well tolerated, with mostly mild and transient adverse events and high adherence in the home-use setting.

Neurolief will participate in APA’s Mental Health Innovation Zone and Med Buzz Hub, and will host a key opinion leader panel on the clinical evidence, mechanism of action and care delivery model supporting Proliv Rx.

The company has also launched a new Proliv Rx website for clinicians, health systems, payors and patients.